| Identification | Back Directory | [Name]
Ubamatamab | [CAS]
2305629-50-7 | [Synonyms]
Ubamatamab
Research Grade Ubamatamab
Research Grade Ubamatamab (DHJ31005) |
| Hazard Information | Back Directory | [Uses]
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity[1]. | [in vivo]
Ubamatamab (REGN4018; 0.01-0.5 mg/kg; i.p; on days 6, 10, 13, 16, and 21) potently inhibits growth of intraperitoneal ovarian tumors[1].
Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity[1]. | Animal Model: | NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells[1] | | Dosage: | 0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg | | Administration: | i.p; on days 6, 10, 13, 16, and 21 | | Result: | Significantly reduced tumor burden, and did not result in any changes in weight. |
| Animal Model: | Cynomolgus monkeys | | Dosage: | 0.01, 0.1, or 1 mg/kg | | Administration: | i.p; once a week; total of five doses | | Result: | Showed minimal and transient increases in serum cytokines and C-reactive protein. |
| [References]
[1] Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. DOI:10.1126/scitranslmed.aau7534 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|